Erasca, Inc. financial data

Symbol
ERAS on Nasdaq
Industry
Pharmaceutical Preparations
Location
10835 Road To The Cure, Suite 140, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.18 K % -7.69%
Debt-to-equity 24.4 % +20.6%
Return On Equity -38.8 % +36.8%
Return On Assets -31.2 % +39%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 151 M shares +0.6%
Common Stock, Shares, Outstanding 151 M shares +1.04%
Entity Public Float 297 M USD -31.2%
Common Stock, Value, Issued 15 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 151 M shares +1.11%
Weighted Average Number of Shares Outstanding, Diluted 151 M shares +1.11%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 38.5 M USD +9.01%
Operating Income (Loss) -143 M USD +42.2%
Nonoperating Income (Expense) 16.5 M USD +95.8%
Net Income (Loss) Attributable to Parent -127 M USD +47%
Earnings Per Share, Basic -0.84 USD/shares +55.8%
Earnings Per Share, Diluted -0.84 USD/shares +55.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76.7 M USD -71.9%
Marketable Securities, Current 221 M USD +88.9%
Cash, Cash Equivalents, and Short-term Investments 298 M USD -23.6%
Assets, Current 307 M USD -22.9%
Property, Plant and Equipment, Net 21.4 M USD -13.3%
Operating Lease, Right-of-Use Asset 37.2 M USD -6.58%
Other Assets, Noncurrent 4.46 M USD -7.86%
Assets 370 M USD -20.9%
Accounts Payable, Current 2.63 M USD -21.5%
Liabilities, Current 30.2 M USD +18.5%
Operating Lease, Liability, Noncurrent 50.8 M USD -7.51%
Other Liabilities, Noncurrent 559 K USD -11.3%
Liabilities 81.6 M USD +0.65%
Accumulated Other Comprehensive Income (Loss), Net of Tax -210 K USD +59.1%
Retained Earnings (Accumulated Deficit) -641 M USD -24.7%
Stockholders' Equity Attributable to Parent 288 M USD -25.4%
Liabilities and Equity 370 M USD -20.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.3 M USD -26.2%
Net Cash Provided by (Used in) Financing Activities 6.93 M USD +3687%
Net Cash Provided by (Used in) Investing Activities 9.97 M USD -32.2%
Common Stock, Shares Authorized 800 M shares 0%
Common Stock, Shares, Issued 151 M shares +0.56%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.3 M USD -42.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77.1 M USD -71.8%
Deferred Tax Assets, Valuation Allowance 144 M USD +10.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 156 M USD +6.13%
Operating Lease, Liability 54.9 M USD -5.37%
Payments to Acquire Property, Plant, and Equipment 42 K USD -96.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -127 M USD +47.1%
Lessee, Operating Lease, Liability, to be Paid 78.4 M USD -9.42%
Property, Plant and Equipment, Gross 29.6 M USD +1.98%
Operating Lease, Liability, Current 4.13 M USD +32.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.17 M USD +1.62%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.02 M USD +3.11%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 23.4 M USD -17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.2 M USD +0.32%
Deferred Tax Assets, Operating Loss Carryforwards 59.3 M USD +13.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 80 M shares 0%
Unrecognized Tax Benefits 4.1 M USD +50.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.28 M USD +0.85%
Operating Lease, Payments 2.1 M USD +143%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.84 M USD +22.5%
Share-based Payment Arrangement, Expense 26.2 M USD +16.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%